DDInter1066 DDInter1435
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Lidocaine {u} (Compound) resembles {v} (Compound) Chloroprocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP2C18
Lidocaine {u} (Compound) palliates {v} (Disease) coronary artery disease
Lidocaine {u} (Compound) is included by {v} (Pharmacologic Class) Local Anesthesia
Lidocaine {u} (Compound) downregulates {v} (Gene) PPP2R5E
Lidocaine {u} (Compound) causes {v} (Side Effect) Nausea
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Butalbital
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Lidocaine (Compound) resembles Ropivacaine (Compound)
Lidocaine (Compound) resembles Chloroprocaine (Compound)
Lidocaine (Compound) binds CYP2C18 (Gene)
Lidocaine (Compound) palliates coronary artery disease (Disease)
Lidocaine (Compound) is included by Local Anesthesia (Pharmacologic Class)
Lidocaine (Compound) downregulates PPP2R5E (Gene)
Lidocaine (Compound) causes Nausea (Side Effect)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab